Breast Cancer

In the phase 3 ASCENT-03 trial, sacituzumab govitecan did not show an OS detriment vs chemotherapy in previously untreated metastatic triple-negative breast cancer.

From breast cancer to head and neck tumors, the 2025 ASCO Annual Meeting may feature a wide range of practice-changing data across cancer care.

AI-assisted training dramatically reduced HER2-null overscoring and improved sensitivity in HER2-low and HER2-ultralow breast cancer cases.

Final OS data from INAVO120 demonstrate, for the first time, a significant OS improvement with a PI3K-targeted agent in this breast cancer population.

"The data, even in fast progressors and within 6 months of endocrine therapy, [show it] is working," stated Monica Khunger Malhotra, MD.

Kit Yu Lu, MD, discusses the applications of T-DXd and sacituzumab govitecan for patients with breast cancer.

Shannon L. Puhalla, MD, delves into the clinical application, efficacy, and safety profiles of T-DXd and sacituzumab govitecan for patients with breast cancer.

Neil M. Iyengar, MD, highlighted the recent T-DXd and Dato-DXd approvals in breast cancer.

Ten-year data from the phase 3 APHINITY trial will be presented at the 2025 European Society for Medical Oncology Breast Cancer Congress.

Policy changes supporting breastfeeding may address structural barriers and lower overall incidence and racial disparities surrounding TNBC in the US.

Neoadjuvant trastuzumab deruxtecan/THP showed an enhanced safety profile vs the standard-of-care regimen in patients with early-stage breast cancer.